Loading
Esophageal Cancer Research and Treatment / Nanoplatforms for Cancer Theranostics / Photodynamic Therapy Research Studies · Journal article
Cancer Science · September 5, 2026
Encouraging direction, but not yet definitive.
This Phase II trial demonstrates that Cosiporfin sodium-mediated photodynamic therapy is tolerable and produces a 40% overall response rate for dysphagia in advanced esophageal cancer patients unsuitable for curative therapy. Dose-limiting toxicities occurred in 16.7–25.0% of patients across higher-dose regimens, and median overall survival was 9.51 months. The results are encouraging but require validation in a larger, controlled trial before clinical implementation.
Phase II, single-arm clinical trial with three dose regimens. Advanced esophageal cancer patients with Grade ≥2 dysphagia who were unsuitable for or declined curative therapies. Intervention: Cosiporfin sodium (DVDMS) 0.2 mg/kg followed by photodynamic therapy (630 nm wavelength) at doses of 102 J/cm (24 h post-injection), 200 J/cm (24 h), or 150 J/cm (18 h). n = 30.
Esophageal overall response rate was 40.0% on day 28 Median overall survival for all patients was 9.51 months (95% CI: 5.45–NE) Median duration of esophageal response was 4.86 months (95% CI: 1.51–5.32)
Highly unequal group sizes (20 vs 6 vs 4) across dose regimens; smallest groups underpowered to detect safety differences Dose-limiting toxicities occurred in 1/6 patients (16.7%) in 200 J/cm 24 h group and 1/4 patients (25.0%) in 150 J/cm 18 h group
Clinicians treating advanced esophageal cancer patients with dysphagia who are ineligible for curative intent therapy may consider DVDMS-PDT as a palliative option, pending validation in a larger controlled trial. The 40% response rate and median survival of 9.5 months suggest potential benefit, but safety signals at higher doses warrant caution.
Phase II trial with modest sample size showing acceptable safety profile and 40% response rate for dysphagia in advanced esophageal cancer, but requires larger confirmatory studies before clinical adoption.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians treating advanced esophageal cancer patients with dysphagia who are ineligible for curative intent therapy may consider DVDMS-PDT as a palliative option, pending validation in a larger controlled trial. The 40% response rate and median survival of 9.5 months suggest potential benefit, but safety signals at higher doses warrant caution.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT Photodynamic therapy (PDT) is a localized treatment for esophageal stenosis and dysphagia in advanced cancer. This study evaluated the efficacy and safety of Cosiporfin sodium (DVDMS)‐mediated PDT for dysphagia in advanced esophageal cancer. In this Phase II trial, patients with advanced esophageal cancer and Grade ≥ 2 dysphagia, who were unsuitable for or declined curative therapies, received 0.2 mg/kg DVDMS followed by PDT (wavelength: 630 nm) at varying regimens: 102 J/cm (24 h post‐injection), 200 J/cm (24 h), and 150 J/cm (18 h). Safety was the primary endpoint. The study enrolled 20 patients in the 102 J/cm 24 h group, 6 in the 200 J/cm 24 h group, and 4 in the 150 J/cm 18 h group. Two patients experienced dose‐limiting toxicities: One upper abdominal pain (16.7%) in the 200 J/cm 24 h group and one non‐cardiac chest pain (25.0%) in the 150 J/cm 18 h group. Common adverse events included non‐cardiac chest pain (10.0%) related to DVDMS and non‐cardiac chest pain (20.0%) and anemia (20.0%) related to PDT. The photosensitivity test showed that by day 4, 66.7% of patients tested negative, improving to 86.7% by day 7, and all patients were negative by day 28. The esophageal overall response rate was 40.0% on day 28. The median duration of esophageal response and median OS for all patients were 4.86 months (95% CI: 1.51–5.32) and 9.51 months (95% CI: 5.45–NE), respectively. DVDMS‐mediated PDT demonstrates acceptable safety and sustained efficacy in improving esophageal stenosis and dysphagia in advanced esophageal cancer. Trial Registration: chictr.org.cn ChiCTR2000032829.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.